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Abstract Multiple myeloma (MM) and AL amyloidosis
are caused by the expansion of monoclonal plasma cells and
secretion of dysproteinemia (Bence Jones protein and free
light chain) and some patients require the hemodialysis.
Myeloma kidney is mainly caused by the cast nephropathy
of the distal tubuli, whereas, AL amyloid-protein is mainly
deposited in glomeruli with massive fibrillar involvement.
Therefore, almost MM patients presents a symptom of renal
insufficiency, whereas, almost patients of AL amyloidosis
present a nephrotic syndrome with severe hypoalbuminemia.
These two diseases have some similar characteristics
such as up-regulation of cyclin D1 gene by 11:14 chromo-
somal translocation. High-dose chemotherapy supported
with autologous peripheral blood stem cells is effective
for these two diseases. However, they are still difficult to
be cured and require long-term disease control. In recent
years, introduction of novel agents has changed their treat-
ment strategies from the palliation therapy to the clinical
cure.
Keywords Multiple myeloma  AL amyloidosis 
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Introduction
Multiple myeloma (MM) is an incurable disease with high
incidence rate in the elderly. Responsiveness to treatments
varies largely among the patients due to high heterogeneity
of MM. Decision of the treatment has been a difficult issue
in MM. However, changes can be seen in its treatment
strategies since good quality of response can be realisti-
cally obtained due to an introduction of novel drugs
(bortezomib, lenalidomide, and thalidomide). This article
reviews the latest trend and the future perspective of
treatment for MM which has advanced remarkably in
recent years.
MM and AL amyloidosis are similar diseases resulting
from clonal proliferation and dysfunction of plasma cells,
in which renal dysfunction due to deposition of immuno-
globulin (M protein/amyloid) or other causes are frequently
observed. Since exacerbation of renal function is closely
associated with the prognosis of patients, maintenance or
improvement of renal function by managing the underlying
disease is required. In recent years, stratification of mye-
loma as high-risk and standard-risk by Mayo group has
been introduced [1]. Deletion of 17p by FISH, t (14:16),
Cytogenetic hypodiploidy, and b2-microglobulin[5.5 and
LDH level [upper limit of normal are high risk sign.
T (4:14) and cytogenetic deletion 13 are considered as
intermediate risk by the reasons of overcoming with new
drugs. After that, IMWG stratification is also published;
Standard-risk were Hyperdiploidy (45 % of MM mainly
IgG type and aged patients), t(11;14)(q13;q32) CCND1:,
and t(6;14) CCND3:. Intermediate-risk were t(4;14)
(p16;q32) MMSET: and deletion 13 or hypodiploidy
by conventional karyotyping. High-risk were 17p dele-
tion, t(14;16)(q32;q23) C-MAF:, and t(14;20)(q32;q11)
MAFB:.
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We classified AL amyloidosis into four groups as
follows; cardiac, renal, gastrointestinal and pulmonary
amyloidosis, and the others according to the main organ
with AL amyloid materials deposition. In this decade,
novel agents (bortezomib, thalidomide and lenalidomide)
have become available to treat multiple myeloma in
Japan. In this article, we review the recent trend for the
diagnosis and treatment strategies of multiple myeloma
and AL amyloidosis by focusing on how to improve renal
lesion.
Diagnosis and treatment of multiple myeloma
Historical perspective
In 1962, Bergsagel et al. [2] reported that L-phenylalanine
mustard (melphalan) could induce remissions in approxi-
mately one third of patients with MM. In 1967, Salmon
et al. [3] reported that high doses of glucocorticoids could
induce remissions in patients with refractory or relapsing
MM. Combination therapy with melphalan and predniso-
lone in 1969 by Alexanian et al. [4] showed a better result
than melphalan alone.
However, the response rate with alkylators and corti-
costeroids was only approximately 50 %, and CR was rare.
Cure was never a goal of therapy as it was assumed
unattainable. Instead, the goal was to control the disease as
much as possible, providing the best quality of life to
patients for the longest duration by judicious, intermittent
use of the 2 available classes of active chemotherapeutic
agents. Also in 1986, clinical studies evaluating HDT with
single ASCT (McElwain) and double ASCT (Barlogie)
were conducted. In 1996, the first randomized study
showed benefits with HDT with ASCT versus standard
chemotherapy. Berenson et al described an efficacy of
bisphosphonate pamidronate in reducing skeletal events in
patients with advanced MM.
In 1999, thalidomide was introduced and the first non-
myeloablative mini-allogeneic transplants were intro-
duced with several novel agents that target the biological
pathway of the disease, as well as long-acting Adriamy-
cin analogues. In the past decade, thalidomide, bort-
ezomib, and lenalidomide have emerged as effective
agents for the treatment of myeloma, producing specta-
cular results in combination with other known agents in
terms of response rate, CR rate, progression-free survival
(PFS), and, more recently, overall survival. In 2001, a
new classification system introduced ‘‘CRAB’’ features of
organ damage (Fig. 1) [5]. In 2004, the International
Staging System was introduced. The results obtained
from new combinations have indeed been remarkable and
have created a relatively new philosophy of treating
myeloma with a goal of potential cure rather than disease
control.
Chemotherapy is indicated for patients with newly
diagnosed symptomatic myeloma, although it is generally
not recommended for patients with monoclonal gammop-
athy of undetermined significance (MGUS), smoldering, or
asymptomatic myeloma. Age, performance status, and
neurologic and co morbid conditions are critical factors in
the choice of initial therapy. Melphalan and prednisone
combination can no longer be considered as a standard of
care in patients who are 65 years of age or older. Our
findings suggest that bortezomib plus melphalan-predni-
sone is the standard front-line treatment for patients with
myeloma who are 65 years of age or older and cannot
tolerate more aggressive treatment [6].
During the past decades, high-dose therapy with autol-
ogous stem-cell transplantation (HDT-SCT) has become
the standard treatment option for patients with untreated
multiple myeloma (MM) who are younger than 65 years of
age; however, HDT-SCT is not usually recommended
for older patients and patients with clinically significant
co-morbidities.
A recent study has shown that long-term survival
improved significantly in younger patients while only
limited improvement was achieved in elderly patients.
Improved treatment for such older patients ineligible for
HDT-SCT was much-awaited.
Should we treat patients with myeloma with multidrug,
multitransplant combinations to pursue the goal of poten-
tially curing a subset of patients, recognizing that the bal-
ance of adverse events and effect on quality of life will be
substantial? Or should we consider myeloma as a chronic
incurable disease with a goal of disease control, using the
least toxic regimens, emphasizing a balance between effi-
cacy and quality of life, and reserving more aggressive
therapy for later lines?
Diagnosis criteria of IMWG (International Myeloma Working Gorup)
MGUS Smoldering MM
S-M Protein <3 g/dL S-M Protein 3 g/dL M Protein
PC 10% PC 10%
No anemia, bone lesions Anemia, bone lesions,
NO “CRAB” “CRAB”
normal calcium and 
kidney function




Fig. 1 Diagnostic criteria of IMWG. Anemia, bone lesions, high
calcium or abnormal kidney function are called ‘‘CRAB’’. We start
any initial treatments at the symptomatic myeloma. MGUS and
smoldering myeloma are only careful following
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Induction therapy for newly diagnosed multiple
myeloma (NDMM)
Effect of novel agents on outcome in NDMM was dra-
matically improved (Fig. 2) [7]. Using the combination
therapies with new drugs, multiple myeloma (MM) is
changing from a incurable disease into either a chronic one
or a curable disease.
Bortezomib
Bortezomib IV is an ubiquitin-proteasome inhibitor and
indicated for the treatment of MM. Bortezomib is a
reversible inhibitor of the chymotrypsin-like activity of the
26S proteasome in mammalian cells. It is cytotoxic to a
variety of cancer cell types in vitro and causes suppression
in tumor growth in vivo in nonclinical tumor models,
including MM. Specifically, bortezomib is effective in MM
via its inhibition of nuclear factor-jB activation, its
attenuation of interleukin-6-mediated cell growth, a direct
apoptotic effect, and possibly antiangiogenic and other
effects [8]. Regarding the treatment of patients who are not
eligible for transplantation, MPT and MPB have shown
significantly better overall survival (OS) benefit than that
of MP and are the recommended treatments [6, 9]. The
proteasome inhibitor bortezomib has been approved in the
USA in 2005 for the treatment of MM patients with a
history of at least one prior therapy, based on results from
the phase III APEX study which showed superiority of
bortezomib over high-dose dexamethasone in patients with
relapsed MM [10]. The majority of treatment guidelines
currently recommend incorporating HDT/SCT into initial
therapy programs for patients who are 65 years of age or
younger and to consider such a therapy for patients
60–70 years of age with good performance status and a
lack of co morbid illnesses since HDT/SCT provides the
highest chance of inducing a complete remission. How-
ever, even when patients achieve CR, the vast majority of
patients will ultimately relapse. The standard frontline
therapy for patients who are 65 years of age or older, and
for patients who are not likely to proceed to HDT/SCT,
consists of oral MP at doses similar to those used in this
study. Combination therapies such as MP (at a dose of
0.25 mg/kg/day) are given orally at doses used for 4 con-
secutive days every 6 weeks, showed superior survival
versus melphalan alone. With MP therapy, an OR rate of
approximately 50 %, a CR rate of 2 to 5 % and a median
time to response of 3–5 months have been historically
reported [4].
Final results of the phase 3 VISTA trial
Recently 5 year OS follow up data has been published. The
data indicates that OS in MPB with 60.1 months follow-up
is significantly superior to that of MP. The OS of MP-B and
MP were 56.4 months (13.3 months improvement) and
43.1 months respectively. This data is very much remark-
able because the OS improvement was 13.3 months
although even MPT could improve only 6.6 months in its
meta analysis. As a result of this VISTA study, MPB
became the standard treatment for untreated transplant
in-eligible patients [11].
To evaluate safety, pharmacokinetics (PK) and efficacy
of bortezomib combined with melphalan and prednisolone
(MPB) therapy, we conducted a phase I/II study for
untreated Japanese MM patients who were ineligible for
hematopoietic stem cell transplant (HSCT). This was a
dose-escalation study designed to determine the recom-
mended dose (RD) of bortezomib in combination with
melphalan and prednisolone by evaluation of the maximum
tolerated dose based on dose-limiting toxicity (DLT) in the
phase I portion, and to investigate the overall response rate
(ORR; CR ? PR) and safety of MPB therapy in the phase
II portion. Particularly, a continuity of treatment cycles was
historically compared with a global phase III study (VISTA
trial), and the incidence of interstitial lung disease was
assessed. This phase I/II study in Japan suggests that the
RD of bortezomib in MPB therapy is 1.3 mg/m2 and the
MPB therapy in newly diagnosed Japanese MM patients
ineligible for HSCT is as effective as that shown in VISTA
trial. Further investigation is necessary to confirm the
























Cs1                       Elotuzumab
CPT-11EHC          Nk012
IL-6                       Siltuximab
Proteasome          MLN9708
Alkylator               Bendamustine 
MPT Initial Tx        
RANKL                 Denosumab
Fig. 2 Effect of novel agents on outcome in newly diagnosed
myeloma. Overall survivals were elongated by the effect of HDT with
ASCT from 1994, longer due to new drugs from 2001. 1970, MP;
1986, HDT with ASCT; 1999–2000, new drugs (bortezomib,
lenalidomide, and thalidomide) were epoch making. The CS-1
antibody (elotuzumab) and IL-6 antibody (siltuximab) may be
effective with some combinations. Bendamustine, a bifunctional
agent, shares properties of alkylating agents and purine analogs. New
combination trials of new agents, as shown in right-side may be
promising
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What should be the goal of treatment in multiple mye-
loma? If cure is the goal, then CR is the critical first step
(Fig. 3) [13]. CR is a treatment goal in many hematological
malignancies, eg- AML, ALL and lymphomas. In the past,
achievement of CR in MM was rare. New treatments can
increase the rate of CR to the similar level with high-dose
therapy followed by ASCT (Fig. 4) [14–16]. Also, CR rate
in Phase 3 trials in non-transplant patients was: MPB 30 %;
MPT 2-16 %; MPR 13 %; MPR-R 18 %, and long term
RD 22 %. MM may not be a single disease cytogenetically;
achievement of CR seems particularly important in the
15 % of patients with high-risk MM, since survival is
similar in patients without high-risk features who have and
have not achieved CR [6, 17–20].
Cyclophosphamide and thalidomide
Cyclophosphamide has been added to thalidomide and
dexamethasone (CTD) with excellent response rates among
newly diagnosed MM patients who received subsequent
SCT, with higher response rates seen after SCT.
The combination in 3-weekly schedules of cyclophos-
phamide (50 mg PO or 300 mg/m2 PO weekly or 150 mg/
m2 d1–5), thalidomide (200–800 mg daily, increasing
doses or intermittent administration 400 mg d1–5 and
d14–18) and dexamethasone (40 mg per day for 4 days)
(CTD) results in an ORR of around 60 %, a median TTP of
10–12 months and a 2-years PFS of 57 % [21–23].
Comprehensive reviews on the use of thalidomide have
been published and include efficacy and safety in relapsed
MM. The rationale for using thalidomide was based on its
antiangiogenic properties because, in MM, increased
microvessel density has been inversely correlated to sur-
vival. However, thalidomide has multiple modes of action,
including immunomodulatory effects. This initial experi-
ence generated a great enthusiasm, and a large number of
phase II trials were rapidly conducted. A systematic review
of such 42 trials on [1600 patients confirm that the
response rate is 29 % with an estimated 1-year overall
survival (OS) of 60 %. The well-known teratogenicity of
thalidomide is not a major concern in patients with MM
because of patients age, but justifies careful informing of
patients and programs to avoid drug exposure in women
with childbearing potential. The major toxicities of tha-
lidomide are fatigue, somnolence, constipation, and mostly
peripheral neuropathy, which are related to the daily dos-
age and to treatment duration. The overall incidence of
peripheral neuropathy is 30 % but may be higher if treat-
ment is prolonged for [1 year. Because this complication
may be disabling and sometimes irreversible, patients
should decrease the dose or stop the treatment if significant
numbness occurs.
Durie BGM, et al. Leukemia 20:1467-73, 2006.
PR VGPR nCR CR sCR
Serum Protein 








Immunofixation Positive Negative Negative
Serum Free Light Chain 
Ratio               Normal
International uniform response criteriaFig. 3 International uniform
response criteria. Serum protein
electrophoresis, serum/urine
immunofixation, and serum free
light chain ratio are important
Impact of CR:
What disease response is best?










• Depth of response is related to TTP
Fig. 4 Impact of CR: depth of response is related to TTP. CR is the
surrogated marker for the long survival
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After induction treatment, two to four cycles of com-
bination therapies is followed by the maintenance therapy,
which is continuous therapy with a single agent, with
reasonable balance between maximum benefits and mini-
mum toxicities [24] until the time of disease progression.
Maintenance therapy for multiple myeloma
I prefer disease control as a treatment goal, except in
selected high-risk patients in whom an aggressive approach
to achieving CR may be the only option to long-term
survival (Fig. 5). The disease control approach involves
targeting very good partial response (minimal residual
disease) rather than CR as a goal by using limited, less
intense therapy first and moving to more aggressive
approaches as need arises (sequential approach): this
allows patients to help determine the timing and number of
transplants.
Post-transplant consolidation/maintenance with novel
agents can become an important step forward. Thus, it has
recently been reported that post-transplant consolidation
with thalidomide, lenalidomide or bortezomib increases the
CR rate. In this regard, it has been shown that post-ASCT
consolidation with VTD can induce long-lasting molecular
remission [25, 26]. Thalidomide maintenance prolonged
the OS in two transplant series [27].
The response rate to treatment with single-agent tha-
lidomide in patients with relapsed and/or refractory MM is
between 30 and 40 % [28].The response rate increases
from 50 to 65 % when thalidomide is combined with
dexamethasone with or without cytotoxic agents.
The cure-versus-control debate is hot. Indeed, CR is a
surrogate marker for improved OS. However, for the
majorities of MM patients, the disease control approach
(Maintenance therapy) involves targeting very good partial
response (VGPR) rather than CR as a goal. This is a pilot
study of the prospective, sequential registered trial of the
Fig. 5 Strategy of myeloma treatment in our institute. We divided in
four phases: initial therapy by two to four courses of BorDex/
CyBorD/ or MPB [66 years old followed by PBSC-harvest. If the
high risk patients, up-front PBSC-transplantation followed by Bor-
maintenance. Otherwise, if the standard risks patients, maintenance-
therapies may be the B-stages until progress disease. PD are defined
as (1) above 10 % elevation of M-protein, (2) hypercalcemia, (3)
anemia progress, (4) bone pain, (5) b2-MG elevation (6) additional
chromosome ab. (7) BM myeloma cell elevation. After PD, problem-
oriented PBSCT may be done with second maintenance with
Lenalidomide
Clin Exp Nephrol (2012) 16:659–671 663
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significance of BD maintenance therapy for long-term
survival with good QoL.
From September 2008, we continued exploratory study of
effects of bortezomib on the ability of patients with relapsed,
refractory multiple myeloma to continue maintenance therapy
[29] (Clin. Eth. No: JRC 170). Bortezomib had been associ-
ated with fatal lung disorders, with a high number of reported
cases in Japan. Post-marketing surveillance, however, showed
a low incidence of 3.6 %. Peripheral neuropathy (20–30 %) is
a major concern. Informed consent was obtained from 43
patients with a mean prior treatment (e.g., VAD, ROAD,
ASCT) history of 23 months, PS B2, and no significant organ
lesions. Efficacy of bortezomib as maintenance therapy in
patients achieving VGPR/PR with remission induction ther-
apy has not been investigated. This study of bortezomib
maintenance therapy in patients achieving VGPR/PR with
bortezomib is therefore investigating the effects of treatment
on patients ability to continue maintenance therapy and
adverse drug reaction incidence. There were 11 cases of
karyotypic abnormalities (35 %) with 8 cases of complex
abnormalities. Patients received dexamethasone (20 mg/
body) daily for 2 days every 2 or 4 weeks with bortezomib,
1.3 mg/m2 div. Time-to-progression (TTP) was the primary
efficacy endpoint (Fig. 6) [29]. The adverse reactions of
BD maintenance include asthenia conditions, peripheral
neuropathy, thrombocytopenia were all G-1 and well
tolerated. Long-term survival with good QoL is the most
important goal for the elderly/low genetic risk MM patients.
BD maintenance is good available for this group (24/43 cases)
over 20 months (Fig. 7), especially in the cases of total
delivery dose over 40 mg. However, the other group of
patients (8/33 cases) in rapidly relapsing with complex
karyotypic abnormalities may need the strong combination
chemotherapy.
Recently, lenalidomide maintenance therapy improved
median progression-free survival (41 vs. 23 months with
placebo; hazard ratio, 0.50; P \ 0.001) [30].
Therapy for relapsed or refractory multiple myeloma
(RRMM)
Progressive disease is defined as follows: (1) Above 25 %
elevation of M-protein, (2) hypercalcemia: corrected serum
calcium [11.5 mg/dL, (3) the absolute increase of free
light chain (FLC) must be [10 mg/dL, (4) definite devel-
opment of new bone lesions or soft tissue plasmacytomas,
(5) decrease in hemoglobin of [2 g/dL, (6) rise in serum
creatinine by 2 mg/dL or more, (7) increase of BM mye-
loma cell above 10 %.
1) 46,XX,t(11;14)(q13;q32)[1]/46,XX[29]             2) 50,add(X)(q28),-X,-1,+3,+7,-8,+9,+15,del(22)(q139,+3mar,inc[cp12]/46,XX[18] 
3) 83~85,XX,-X,-X,der(1;2)(q10;q10)- 2,-2,-2,-3,add(3)(p2?),-4,-4,add(4)(p16),add(4)(p16),-5,-5,-6,-6,-8,add(10)(q22)2,-13,-13,-

















M-protein levels over time in IgG type (n=26)
1)
Fig. 6 Maintenance therapy with bortezomib for the VGPR IgG-
myeloma patients. Monthly administration of bortezomib are effec-
tive as the stabilization of M-protein levels over time in IgG type
(n = 26). It needs 20 months average until PD. However, high risk
group are difficult to control in this manner
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Analysis of second primary malignancies (SPM)
Another important issue in MM is risk of developing SPMs
due to living longer from diagnosis. Population studies
show MM patients have increased risk of specific SPMs
following initial diagnosis, notably acute myeloid leukemia
(AML). Some MM therapeutic agents are particularly
associated with elevated risk of SPMs. Melphalan is
associated with increased risk of secondary acute leukemia.
There were imbalances in SPM incidence, including
myeloid and lymphoid leukemias, with post-transplant
lenalidomide maintenance therapy and with MP-lenalido-
mide. Persistent significant OS benefit with VMP versus
MP; 13.3-months increase in median, and MPT versus MP
increase 6.6 months [9].
Secondary malignancies and lenalidomide: by summa-
rizing the data to-date, the incidence of all/invasive SPM is
significantly increased in Lenalidomide arms, driven by
hematologic SPM (P \ 0.001). B-ALL, Hodgkin lym-
phoma is reported in post high-dose melphalan and ASCT
setting. Sensitivity analysis (including SPM as an event)
demonstrates negligible PFS differences. The overall ben-
efit–risk profile of lenalidomide in NDMM remains posi-
tive [31, 32]. Risk Factors for Secondary Malignancies
Treatment with lenalidomide may be treatment duration
[24 months, male, age [55 years, ISS stage III, previous
DCEP (role of concomittant or previous exposure to
alkylators?) induction by univariate and multivariate
analysis in IFM 2005.
In Japanese SPM Report by JRCMC, retrospective
analysis for 325 MM patients from 1998 to 2010 (13 years)
showed t-MDS/AML developed 17 (5.2 %) patients.
Median time to onset: 52 months in t-AML and months in
t-MDS. All the patients with t-AML died in a short time,
suspected to be treated with Melphalan, and no patients had
been given Lenalidomide. We have to select chemo regi-
men taking into account the risk of t-MDS/AML [33].
Renal dysfunction in multiple myeloma
Timing of treatment initiation in multiple myeloma is
depending on existence of organ dysfunction. Usually
when any symptom such as bone symptoms, renal dys-
function, anemia, or hypercalcemia is observed, it is
diagnosed as symptomatic multiple myeloma and treatment
should be started. Renal dysfunction in multiple myeloma
is one of the complications that require the most careful
attention and occurs via various mechanisms. Of these, the
most frequent case is cast nephropathy, also known as
myeloma kidney, in which excessive light chains of M
protein (BJP) secreted by proliferated plasma cells form
cast by depositing themselves in renal tubules. In addition,
hypercalcemia associated with osteolysis by myeloma
cells, deposition of amyloid in glomeruli, hyperviscosity
syndrome, hyperphosphatemia, renal infiltration of mye-
loma cells are also the causes of renal dysfunction. Other
than those, care must be given to recurring urinary tract






























Onset in February 2009.Underwent 3 courses of MP and was transferred to 
my hospital in May 2009 because of poor response. 
Initial data: 13q-[FISH], Cr 3.87 mg/dl, IgG 5979 mg/dl, bone scintigraphy 
showing  accumulation in skull, 11th rib, and vertebrae.
Case: 81-year-old woman Type: IgGλ+BJPλ, IIIb
In hospital
Elderly patient living far from hospital, able to visit only once monthly. Achieved CR when 
switched from VGPR to maintenance therapy.
Outpatient (with monthly treatment)
Creacinin
Fig. 7 A case of Bor-
maintenance therapy. Elderly
patient (81 year old female:
IgGk ? BJPk, stage IIIb) living
far from hospital, can visit only
once monthly. After 14 months
therapy, she achieved CR when
switched from VGPR to
maintenance therapy
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factor. According to the statistics of Japanese Society of
Myeloma [34], approximately 15 % of newly diagnosed
multiple myeloma patients have complication of renal
dysfunction and the rate increases as the disease pro-
gresses. Bence Jones protein (BJP) type and IgD type of
myeloma that excrete high amount of Bence Jones protein
into urine show high frequency of renal dysfunction. In 197
patients diagnosed as multiple myeloma during 12 years
(1995–2006) in our facility, 3.6 % of IgG type and 8.9 %
of IgA type showed higher than 2 mg/dL of creatinine on
the first visit, were whereas BJP type accounted for 36.8 %
(Fig. 8). Because renal dysfunction becomes irreversible if
timing of treatment is missed, immediate treatment is
necessary. It is reported that renal dysfunction remains
reversible when serum creatinine is below 4 mg/dL, Ca is
below 11.5 mg/dL and urine protein is 1 g/day or lower
[35]. Although these are the data before introduction of
novel agents, in the 423 patients with newly diagnosed
multiple myeloma, patients with renal dysfunction (22 %)
showed significantly shorter survival time compared to the
patients with normal renal function (8.6 vs. 34.5 months).
In addition, Blade et al. reported that in the same patients
with reduced renal function, those who recovered their
renal function by subsequent chemotherapy showed sig-
nificantly extended survival time compared to those with-
out recovery of renal function (28.3 vs. 3.8 months).
Therefore, although renal dysfunction in multiple myeloma
is a poor prognostic factor, good prognosis can be expected
if the treatment restores renal function. For this, it is
important to restore renal function by implementing
effective treatment in patients with renal dysfunction
before it becomes irreversible and requires hemodialysis.
In the multiple myeloma patents in our facility mentioned
above, hemodialysis was introduced to eight out of 197
cases.
Improvement of renal function and treatment strategy
for multiple myeloma
Improvement of the primary disease is the basic remedy of
renal dysfunction that complicates with multiple myeloma.
Since 2005, treatment strategy for multiple myeloma has
significantly changed due to the successive introduction of
novel agents. The three drugs including a proteasome
inhibitor bortezomib, and two immunomodulatory drugs
(IMiDs), lenalidomide and thalidomide, are referred to as
novel agents, and each drug has characteristic profiles of
efficacy and safety. While all those agents can be expected
to restore renal function due to improvement of the primary
disease, bortezomib, with strong antitumor effect, is
reported to rapidly improve renal function (Fig. 9). Rous-
sou et al. retrospectively compared improvement of renal
function among traditional chemotherapy group, IMiDs
(lenalidomide or thalidomide)-based treatment group, and
bortezomib-based treatment group with 96 cases of newly
diagnosed multiple myeloma. It showed that the best and
the most rapid improvement of renal function were
observed in the bortezomib-based treatment group. Renal
response rate (minor response and better) based on creatine
clearance improvement and time to response as 59 % and
1.8 months in chemotherapy group, 79 % and 1.6 months
in IMiDs-based group, and 94 % and 0.69 month in bort-
ezomib-based group, respectively [36]. In addition, some
cases with withdrawal from dialysis are also reported.
Thus, administration of bortezomib should be considered in
patients with acute or severe renal dysfunction if it is
possible.
Lenalidomide
Lenalidomide is an anti-myeloma drug possessing dual
functions of antitumor effect and immunomodulating
activity. Because lenalidomide is urinary excreted, its
blood concentration increases in patients with renal dys-
function which leads to high incidence risk of adverse
reactions [37]. However, lenalidomide itself has no renal
toxicity and clinical studies showed improvement of renal
function in the patients treated with lenalidomide. Lena-
lidomide can be administrated by proper adjustment of its
dose corresponding to renal function according to the
package description [38]. In fact, it is reported that adjusted
dosing of lenalidomide to patients with renal dysfunction
resulted with similar anti-myeloma efficacy to those with
normal renal function [39, 40], and recovery of renal
function was also observed [41]. Similar to bortezomib,














Initial creacinin levels over 2mg/dl
8 HD induction cases over 12 years
1995 2006 of 197 cases suffering multiple myeloma




Fig. 8 HD induction cases suffering MM. Initial creatinine levels
over 2 mg/dL were 10–20 %, mainly in BJP and IgD type. HD
induction was also frequent in these populations
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Stratified analysis of lenalidomide/dexamethasone therapy
by age showed similar efficacy and tolerability in elderly
(over 65 years of age) to those of youth [43]. Hence this
therapy is considered to be useful especially for elderly
patients with renal dysfunction if the dose is properly
adjusted corresponding to the renal function. Thalidomide
does not require dose control depending on renal dys-
function, but it has not been reported in large studies that
thalidomide is effective on the improvement of renal
function. In any case, early diagnosis and timing of initi-
ation of treatment are important. In addition, full under-
standing of efficacy and safety profiles of novel agents and
using them in combination with existing drugs appropriate
for individual patients are the basis of treatment strategy.
Diagnosis of AL amyloidosis and renal dysfunction
AL amyloidosis is a disease with poor progression in which
deposition of amyloid causes multiple organ failure.
Amyloid consists of immunoglobulin light chains secreted
from monoclonal proliferated plasma cells. Its relative
disease MM is often complicated with AL amyloidosis. In
spite of the fact that it has the same chromosome translo-
cation such as t (11:14) to MM, it shows different patho-
logical condition (Fig. 10). This may be due to slight
difference of translocation breakpoint between AL
amyloidosis and MM. However, the disease mechanism
remains unknown.
It is classified to cardiac, renal, gastrointestinal, and
pulmonary amyloidosis depending on the main organ with
amyloid deposition. The symptoms vary and the most
common cause of death is cardiac failure. The diagnosis is
based on confirmation of amyloid deposition in the
involved organs. When AL amyloidosis is suspected in
patients with clinical findings such as general malaise,
edema, heart failure, tubercle in margin of tongue, and skin
nodule with stigma, biopsy of organs should be first con-
ducted to confirm deposit of amyloid (Fig. 11). Amyloid is
positive with Congo red stain and has positive signal under
polarized light with the polarizing filters. AL amyloidosis
is definitely diagnosed by confirming monoclonal prolif-
eration of plasma cells through identification of M protein
and/or staining pattern of cell surface antigens in addition
to deposition of amyloid. Low detection sensitivity of M
protein even in immunofixation in AL amyloidosis has
been a problem so far. However, the free light chain (FLC)
assay that has listed itself in insurance coverage in 2011 in
Japan, allows over 90 % detection and is reported to be
effective in diagnosis. Amyloid deposits are predominantly
composed of amyloid fibrils which are very stable struc-
tures with a common cross core fold. Deposits are always
rich in proteoglycans and glycosaminoglycans, some of
which are tightly associated with the fibrils and further
Fig. 9 Complete response (CR)
renal. CR may be attained by
bortezomib-based regimen not
only the high levels percentage
but also time to response.
5-stage is divided as the figure
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Fig. 10 Correlation of
pathogenesis between MM, AL
amyloidosis and Mantle cell
lymphoma by the up-regulated
cyclin D1 function. Mantle cell
lymphoma is high tumor growth
with 100 % t (11:14), MM have
10–20 % t (11:14) with
moderate growth and secretary
Ig functions. Some strange and
rear MM patients (i.e. IgM-type,
IgE-type, non-secretary-type)
showed translocation 11:14 over
80 %. Otherwise, AL
amyloidosis showed 30–50 % t
(11:14). There may be the




Bone marrow Plasma cells; 6 %
Fig. 11 Histology of bone marrow and kidney. Tubercle in margin of
tongue is important finding for diagnosis. The amyloidogenic plasma
cell clone is mature type mainly CD19 negative clone. We can see
amyloid deposition in blood vessels of bone marrow in some cases.
Congo-red staining and amyloid fibrils by EM is important by the low
detection with light chain staining
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stabilize them against proteolytic degradation by phago-
cytes and affinities of selective organ deposition..
Renal dysfunction in AL amyloidosis is frequently
caused by glomerular injury due to deposit of amyloid and
observes high albuminuria and nephrotic syndrome. Its
progression leads to kidney failure, and in many cases
requires dialysis.
Therapy of AL amyloidosis
The target of chemotherapies is the amyloidogenic clonal
plasma cells in the bone marrow. Complete remission is the
normalized kappa/lambda ratio of serum FLC, the surro-
gate markers. Similar to MM, the recovery of function in
the damaged organ requires the improvement of primary
disease. However, the recovery from renal dysfunction
with amyloid deposits requires a longer complete remission
period. High-dose chemotherapy followed by autologous
peripheral blood stem cells (ASCT) is effective in treating
AL amyloidosis (Fig. 12).
The response criteria are roughly classified into hema-
tological response comprised of elimination of M protein,
etc. and organ response. In case of renal dysfunction, it is
judged by decrease of albumin. The four-year survival rate
in transplantation group and non-transplantation group is
71 and 41 %, respectively, showing higher survival rate in
transplantation group [44], and in the patients who survive
over 1 year and obtain complete remission after ASCT,
over 10 years of prognosis can be expected [45]. In our
faculty, we conducted high dose chemotherapy with
ASCT during 2005–2010 in 15 patients with renal amy-
loidosis who were 65 years old or younger and had good
PS, and every case showed good results (Fig. 13). Poor
Fig. 12 Autologous stem cell transplantation (ASCT) for AL amy-
loidosis. ASCT in the early stage of AL amyloidosis is effective for
the OS and good QOL. In our experiences, group of ASCT showed
good OS compared with the others (P = 0.00321)
Fig. 13 Effect of ASCT for renal type of AL amyloidosis. Early recoveries of the albumin concentration occurred by ASCT in the early stage
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prognostic factors in high-dose chemotherapy are poor
PS, symptomatic cardiac failure, organ failure in more
than two organs (heart and kidney), and old age (over
65 years of age), and these cases are non-transplant
candidates [46]. MD (melphalan and dexamethasone),
thalidomide (Thal/Dex), cyclophosphamide-thalidomide
(CTD), and the combinations of MM therapy are the first
option for the transplant ineligible. In MD therapy,
approximately 60–70 % of hematological improvement
and approximately 50 % of improved organ were observed
[47]. In overseas, clinical studies are conducted on novel
agents (lenalidomide, thalidomide, and bortezomib) of
myeloma in combination with melphalan, dexametha-
sone and cyclophosphamide against AL amyloidosis. Of
these, bortezomib is considered most promising because
improvement of organs can be expected in addition to its
rapid hematological improvement with high rate. On the
other hand, peripheral neuropathy and cardiotoxicity were
reported as major adverse events of bortezomib, patients
have to be carefully observed with these complications.
Lenalidomide shows poor tolerability in AL amyloidosis
patients at 25 mg/day which is a standard dose in multiple
myeloma, and its MTD is 15 mg/day in AL amyloidosis.
Around 50–70 % of hematological improvement and
around 20–50 % of improvement in organs was reported
in lenalidomide therapy of AL amyloidosis [48, 49].
Appropriate use of lenalidomide depending on the state of
patients should be considered because it has a different
profile of adverse events from bortezomib. Because tha-
lidomide and lenalidomide were reported to worsen renal
function in patients with renal amyloidosis, careful mon-
itoring should be given when used in such patients.
Transplantation of the involved organs is also an option in
the overseas.
Conclusion
As mentioned above, the therapy and treatment strategy of
MM and AL amyloidosis have largely changed in these
recent years. At same time, it is becoming more important
to control the disease in a long-term fashion, maintaining
QoL of patient because it is still difficult to cure the dis-
ease. The increase in the number of treatment options
means that personalized medicine which selects a treatment
corresponding to the systemic condition of the patient, and
the purpose of the treatment will be more important. It is
important to treat MM as chronic disease by taking into full
consideration efficacy and safety of novel drugs and by
effectively combining them with existing drugs. Also we
should consider how we could help patients through the
treatment to live long actively in the society.
MM and AL amyloidosis are caused by functional
abnormality of monoclonal plasma cells, and high-dose
chemotherapy supported with autologous peripheral blood
stem cells is effective to these diseases. However, they are
still difficult to be cured and require long-term disease
control. In recent years, introduction of novel agents has
changed their treatment strategies.
Better understanding of the biology of the amyloido-
genic plasma cell clone and the molecular mechanisms
underlying the light chain misfolding, tissue targeting and
toxicity will define disease-related prognostic criteria.
Risk-adapted therapeutic strategies may be required.
However, it is important to take these diseases as
chronic diseases. For this purpose, early diagnosis and
timing of initiation of treatments is important. Moreover,
understanding of characteristics of novel agents and using
them in combination with existing drugs appropriately for
individual patient is critical. In addition, collaboration with
renal medicine is essential to avoid introduction of dialysis.
Also we should consider how we could help patients by
treatment to live long actively in the society.
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